About Adimab
Adimab is a company based in Lebanon (United States) founded in 2007 by Errik Anderson. Adimab has raised $35.39 million across 6 funding rounds from investors including Orbimed, Google Ventures and Borealis Ventures. The company has 121 employees as of December 31, 2021. Adimab offers products and services including Yeast-based Platform and T Cell Engager Platform. Adimab operates in a competitive market with competitors including Aphios, CDI Labs, OmniAb, QuaDRAD and AbCheck, among others.
- Headquarter Lebanon, United States
- Employees 121 as on 31 Dec, 2021
- Founders Errik Anderson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adimab, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.39 M (USD)
in 6 rounds
-
Latest Funding Round
$14 M (USD), Series F
Apr 02, 2012
-
Investors
Orbimed
& 4 more
-
Employee Count
121
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adimab
Adimab offers a comprehensive portfolio of products and services, including Yeast-based Platform and T Cell Engager Platform.
Generates human antibodies and multispecifics for therapeutics.
Develops multispecific leads for immune therapies.
People of Adimab
Unlock access to complete
Unlock access to complete
Funding Insights of Adimab
Adimab has successfully raised a total of $35.39M across 6 strategic funding rounds. The most recent funding activity was a Series F round of $14 million completed in April 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adimab
Adimab has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Google Ventures and Borealis Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm investing in seed & series A startups
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Adimab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adimab
Investment portfolio details for Adimab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adimab
Detailed financials for Adimab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adimab Comparisons
Peer comparison for Adimab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adimab
Adimab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aphios, CDI Labs, OmniAb, QuaDRAD and AbCheck, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cancer and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Autoantibody detection and profiling products and services are provided.
|
|
| Locked | Locked | Locked |
Transgenic animal platforms are developed for human therapeutic antibody production.
|
|
| Locked | Locked | Locked |
Antibody drug discovery platform
|
|
| Locked | Locked | Locked |
Developer of human therapeutic antibodies
|
Detailed competitors of Adimab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adimab
Complete news archive for Adimab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adimab
Adimab was founded in 2007.
Adimab is headquartered in Lebanon, United States.
Adimab is a funded company, having raised a total of $35.39M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Adimab is 121.
Adimab was founded in 2007 and is based in Lebanon, United States. Operations focus on the biotechnology sector, where an antibody discovery and optimization platform is utilized for autoimmune and infectious diseases. Diverse panels of therapeutically relevant antibodies are delivered and refined to satisfy criteria including affinity, epitope coverage, species cross-reactivity, and developability. The platform supports research and development needs in these therapeutic areas.
Adimab offers Yeast-based Platform and T Cell Engager Platform.
Adimab has 5 investors. Key investors include Orbimed, Google Ventures, Borealis Ventures, Polaris Partners, and SV Health Investors.